{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T03:32:46Z","timestamp":1783654366488,"version":"3.55.0"},"reference-count":23,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T00:00:00Z","timestamp":1768780800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,1,19]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Antimicrobial resistance threatens oral treatment options for acute uncomplicated urinary tract infection (uUTI). Gepotidacin (Blujepa) is a novel oral triazaacenaphthylene antibiotic evaluated in Phase 3 trials versus nitrofurantoin.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To pool Phase 3 randomized evidence comparing gepotidacin and nitrofurantoin for efficacy and safety in female uUTI.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>PRISMA-compliant systematic review and random-effects meta-analysis of Phase 3 randomized controlled trials. Two investigators independently screened records (using Rayyan), extracted data and assessed risk of bias with RoB 2; certainty was rated with GRADE. Outcomes were pooled as risk ratios (RR) or mean differences with 95% confidence intervals (CI) using RevMan 5.4.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Three trials (EAGLE-2, EAGLE-3 and EAGLE-J) including 3510 participants (gepotidacin n\u200a=\u200a1853; nitrofurantoin n\u200a=\u200a1657) were included. Gepotidacin increased composite therapeutic success versus nitrofurantoin (RR 1.20; 95% CI 1.10\u20131.31; I2 = 0%; P\u200a&amp;lt;\u200a0.001) and improved microbiological eradication (RR 1.14; 95% CI 1.07\u20131.21; I2 = 2%; P\u200a&amp;lt;\u200a0.001). Gastrointestinal adverse events were more frequent with gepotidacin (diarrhoea RR 5.51; 95% CI 4.08\u20137.45; nausea RR 2.49; 95% CI 1.56\u20133.97). Serious adverse events were rare and similar between groups. Certainty of evidence per outcome is presented in Table S2 (available as Supplementary data at JAC Online).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Gepotidacin provides superior composite and microbiological outcomes relative to nitrofurantoin for female uUTI but is associated with increased mild-to-moderate gastrointestinal toxicity. Long-term tolerability and resistance surveillance are recommended.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/jac\/dkaf469","type":"journal-article","created":{"date-parts":[[2025,12,6]],"date-time":"2025-12-06T13:00:09Z","timestamp":1765026009000},"source":"Crossref","is-referenced-by-count":1,"title":["Safety and efficacy of gepotidacin in urinary tract infection: a GRADE-assessed systematic review and meta-analysis"],"prefix":"10.1093","volume":"81","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-6970-8261","authenticated-orcid":false,"given":"Taha","family":"Ibrahim","sequence":"first","affiliation":[{"name":"Department of Medicine, Dow University of Health Sciences , Karachi ,","place":["Pakistan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad","family":"Burhan","sequence":"additional","affiliation":[{"name":"Department of Medicine, Dow University of Health Sciences , Karachi ,","place":["Pakistan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad Abdullah","family":"Naveed","sequence":"additional","affiliation":[{"name":"Department of Medicine, Dow University of Health Sciences , Karachi ,","place":["Pakistan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahila","family":"Ali","sequence":"additional","affiliation":[{"name":"Department of Medicine, Dow University of Health Sciences , Karachi ,","place":["Pakistan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zain Ul Abideen","family":"Shahid","sequence":"additional","affiliation":[{"name":"Department of Medicine, Dow University of Health Sciences , Karachi ,","place":["Pakistan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faiqah","family":"Nizam","sequence":"additional","affiliation":[{"name":"Department of Medicine, Jinnah Sindh Medical University , Karachi ,","place":["Pakistan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jawaria","family":"Ibrahim","sequence":"additional","affiliation":[{"name":"Department of Medicine, Hamdard College of Medicine and Dentistry , Karachi ,","place":["Pakistan"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,1,19]]},"reference":[{"key":"2026011902094609000_dkaf469-B1","doi-asserted-by":"publisher","first-page":"e1101","DOI":"10.1093\/infdis\/jiae331","article-title":"Risk factors for recurrent urinary tract infections among women in a large integrated health care organization in the United States","volume":"230","author":"Ackerson","year":"2024","journal-title":"J Infect Dis"},{"key":"2026011902094609000_dkaf469-B2","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1007\/s00345-021-03913-0","article-title":"Global, regional, and national burden of urinary tract infections from 1990 to 2019: an analysis of the global burden of disease study 2019","volume":"40","author":"Zeng","year":"2022","journal-title":"World J Urol"},{"key":"2026011902094609000_dkaf469-B3"},{"key":"2026011902094609000_dkaf469-B4","author":"Blakeslee"},{"key":"2026011902094609000_dkaf469-B5"},{"key":"2026011902094609000_dkaf469-B6","first-page":"771","article-title":"Diagnosis and treatment of acute uncomplicated cystitis","volume":"84","author":"Colgan","year":"2011","journal-title":"Am Fam Physician"},{"key":"2026011902094609000_dkaf469-B7"},{"key":"2026011902094609000_dkaf469-B8"},{"key":"2026011902094609000_dkaf469-B9","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1016\/j.jiph.2019.05.012","article-title":"Oral treatment options for patients with urinary tract infections caused by extended spectrum \u03b2eta-lactamase (ESBL) producing Enterobacteriaceae","volume":"12","author":"Raja","year":"2019","journal-title":"J Infect Public Health"},{"key":"2026011902094609000_dkaf469-B10","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1016\/S0140-6736(23)02196-7","article-title":"Oral gepotidacin versus nitrofurantoin in patients with uncomplicated urinary tract infection (EAGLE-2 and EAGLE-3): two randomised, controlled, double-blind, double-dummy, phase 3, non-inferiority trials","volume":"403","author":"Wagenlehner","year":"2024","journal-title":"Lancet"},{"key":"2026011902094609000_dkaf469-B11","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"2026011902094609000_dkaf469-B12","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1186\/s13643-016-0384-4","article-title":"Rayyan-a web and mobile app for systematic reviews","volume":"5","author":"Ouzzani","year":"2016","journal-title":"Syst Rev"},{"key":"2026011902094609000_dkaf469-B13","author":"National Library of Medicine"},{"key":"2026011902094609000_dkaf469-B14"},{"key":"2026011902094609000_dkaf469-B15","author":"Cochrane Collaboration"},{"key":"2026011902094609000_dkaf469-B16","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1080\/17460913.2025.2460387","article-title":"Plain language summary: efficacy and safety of gepotidacin, a new oral antibiotic, compared with nitrofurantoin, a commonly used oral antibiotic, for treating uncomplicated urinary tract infection","volume":"20","author":"Wagenlehner","year":"2025","journal-title":"Future Microbiol"},{"key":"2026011902094609000_dkaf469-B17","doi-asserted-by":"publisher","DOI":"10.21037\/gpm.2018.08.01","article-title":"Support for nitrofurantoin in uncomplicated urinary tract infections","volume":"1","author":"Schmiemann","year":"2018","journal-title":"Gynecol Pelvic Med"},{"key":"2026011902094609000_dkaf469-B18","doi-asserted-by":"publisher","first-page":"14","DOI":"10.18773\/austprescr.2019.002","article-title":"Nitrofurantoin and fosfomycin for resistant urinary tract infections: old drugs for emerging problems","volume":"42","author":"Gardiner","year":"2019","journal-title":"Aust Prescr"},{"key":"2026011902094609000_dkaf469-B19","doi-asserted-by":"publisher","first-page":"1781","DOI":"10.1001\/jama.2018.3627","article-title":"Effect of 5-day nitrofurantoin vs single-dose fosfomycin on clinical resolution of uncomplicated lower urinary tract infection in women: a randomized clinical trial","volume":"319","author":"Huttner","year":"2018","journal-title":"JAMA"},{"key":"2026011902094609000_dkaf469-B20"},{"key":"2026011902094609000_dkaf469-B21"},{"key":"2026011902094609000_dkaf469-B22","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1053\/j.ajkd.2023.08.009","article-title":"Urinary tract infections: core curriculum 2024","volume":"83","author":"Al Lawati","year":"2024","journal-title":"Am J Kidney Dis"},{"key":"2026011902094609000_dkaf469-B23","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1097\/JU.0000000000000296","article-title":"Recurrent uncomplicated urinary tract infections in women: AUA\/CUA\/SUFU guideline","volume":"202","author":"Anger","year":"2019","journal-title":"J Urol"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/81\/2\/dkaf469\/66444129\/dkaf469.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/81\/2\/dkaf469\/66444129\/dkaf469.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T07:09:53Z","timestamp":1768806593000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/article\/doi\/10.1093\/jac\/dkaf469\/8429096"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,19]]},"references-count":23,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,1,19]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dkaf469","relation":{},"ISSN":["0305-7453","1460-2091"],"issn-type":[{"value":"0305-7453","type":"print"},{"value":"1460-2091","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,2]]},"published":{"date-parts":[[2026,1,19]]},"article-number":"dkaf469"}}